SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets. Errol De Souza, President and CEO of Neuropore, stated, "We are very excited to establish this collaboration with BenevolentAI. The application of artificial intelligence to the elaboration of novel approaches to medicine is one of the leading edges of science and is an approach that is bound to lead to new discoveries. Neuropore's Autophagy Platform is a perfect testing ground for new hypotheses and discoveries. In addition to its drug discovery capabilities, Neuropore's development and translational experience in degenerative disease makes it a great fit for both companies."

AI is transforming how we do business at an unprecedented pace, but the transition to becoming AI-driven is easier than you think. Now is the time to invest and remain at the top of your game. A few weeks ago Artificial Intelligence was thrown into the spotlight as the winners of this year's Turing award, widely known as computing's "Nobel Prize", were announced. Yoshua Bengio, Geoffrey Hinton and Yann LeCun were recognized for their pioneering work over a 30-year period on AI. In the 80s, when AI research was very unfashionable, the trio were motivated by the idea of creating algorithms that could operate, at least at the level of metaphor, like a brain. Neurons in the brain work as an ensemble, together learning internal representations of the input they observe, and these researchers believed their artificial neural networks could do the same.

Our lives are increasingly affected by algorithms. People may be denied loans, jobs, insurance policies, or even parole on the basis of risk scores that they produce. Yet algorithms are notoriously prone to biases. For example, algorithms used to assess the risk of criminal recidivism often have higher error rates in minority ethic groups. As ProPublica found, the COMPAS algorithm – widely used to predict re-offending in the US criminal justice system – had a higher false positive rate in black than in white people; black people were more likely to be wrongly predicted to re-offend.

Scientists have developed an automated system that uses artificial intelligence (AI) to detect and capture fast radio bursts (FRBs) in real-time. FRBs are mysterious and powerful flashes of radio waves from space, thought to originate billions of light years from the Earth, said researchers from Swinburne University of Technology in Australia. They last for only a few milliseconds or a thousandth of a second and their cause is one of astronomy's biggest puzzles. Astronomical Society, has already identified five bursts -- including one of the most energetic ever detected, as well as the broadest. Wael Farah from Swinburne University of Technology trained the on-site computer at the Molonglo Radio Observatory in Australia to recognise the signs and signatures of FRBs, and trigger an immediate capture of the finest details seen to date.

As language learning makes a sea change to online, users will come to expect personalized learning experiences. China's AI-powered online education market alone reached $568 million in 2017 and is expected to surpass $26 billion in 2022. At Sana Labs, we build AI technologies to power these learning experiences through easy to integrate APIs. This means that machine learning models for personalization as well as pronunciation, grammar, and overall fluency feedback can be production ready in days, not months. In this article, I'll highlight why deep learning will power this shift.

Sensyne Health, a British artificial intelligence technology company, has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenue for Sensyne Health of £5 million across the two-year collaboration. Sensyne Health's partner National Health Service trusts will receive a 4% share of all revenue generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years.

Esteban Granero, who plays for Spanish side Espanyol, is CEO of AI consultancy Olocip. A head coach sees his team take the lead in a crucial match with 20 minutes remaining. One assistant advises the coach to drive his players forward, to keep attacking in the hope of a decisive second goal. The other favors more cautious tactics, dropping players back to focus on defending the narrow lead. The coach might draw on his past experience to make his decision or he might just go with instinct -- his gut feeling in that moment of what will win the match.

Stroke patients or others with neurological injury are turning to the rehabilitation powers of robots with artificial intelligence that help people regain previously lost mobility. BIONIK Laboratories, a global health care company with an office in Watertown, develops robotic "InMotion" systems for the arm, hand and wrist. The FDA-cleared products, which are used in hospitals and rehabilitation facilities, work seamlessly by guiding patients with the help of a physical therapist through various movement activities displayed on a monitor. Once the patient has a hand and arm in the InMotion device, robotic therapy takes over, using artificial intelligence to provide the patient as much assistance as needed to work through a series of movements aimed at regaining the patient's mobility. Dr. Eric Dusseux, CEO of BIONIK, said, "We have demonstrated that by using robotic therapy, you can heal faster and better than any conventional therapy. Dusseux said the autonomy and self-esteem experienced by patients using the robots "is exactly what you need when you're a patient suffering from neurological disease." The system even has therapies styled like video games for younger patients. A typical session with the robot may last 30 minutes to an hour, with thousands of people using the 250 systems that have been implemented in over 20 countries. Dusseux said the artificial intelligence data is processed to help patients and doctors get a good idea of progress, often boosting the spirits of those who are frustrated with their limited mobility. "You can imagine the support for the first time after your stroke.

Artificial Intelligence company, TAIGER, announces today the opening of two new offices in Dubai and Hong Kong. Following successes in Singapore, this move is a strategic step to offer organizations information processing and knowledge representation AI to improve and optimize whole of organization work processes globally. TAIGER's AI solutions applies advanced semantic and human-reasoning, along with machine learning and natural language processing to deliver an unrivalled accuracy of 90% and above in 3 key enterprise work processes – information extraction, virtual assistance and enterprise search. These cities were chosen after successful operations in finance, government, legal, hospitality and healthcare industries and expansion with a specialized team in consultative sales and technical support will allow for higher focus and closer relationships with existing and potential clients and partners. Positioned as one of the fastest growing start-ups in Singapore, this expansion follows TAIGER's largest funding round with a Series B totaling USD 25 Million.